Literature DB >> 28007111

Validation of the Spanish Catquest-9SF in patients with a monofocal or trifocal intraocular lens.

Mats Lundström1, Fernando Llovet2, Andrea Llovet2, Mercedes Martinez Del Pozo2, Blas Mompean2, José-Vincente González2, Konrad Pesudovs2.   

Abstract

PURPOSE: To validate the Spanish Catquest-9SF and study patient-reported visual function after implantation of a trifocal versus a monofocal intraocular lens (IOL).
SETTING: Clinica Baviera, Valencia and Madrid, Spain.
DESIGN: Prospective case series.
METHODS: The Catquest-9SF was translated from English to Spanish according to a standard procedure. The Spanish version was validated through Rasch analysis. Patients completed the Catquest-9SF before cataract surgery and 3 months after the surgery. The change in patient-reported visual function caused by surgery, the level of achieved visual function, and satisfaction with vision after surgery were assessed for bilaterally implanted trifocal IOLs versus monofocal IOLs.
RESULTS: The Spanish Catquest-9SF showed very good psychometric properties. Patient-reported achieved visual function was significantly better for those with a trifocal IOL than for those with a monofocal IOL (P < .001). This was also true when the groups were matched for age and ocular comorbidity (P = .006). In multivariate analyses of all cases and matched cases (the same age and no comorbidity), the reported visual function was significantly better with trifocal IOLs than with monofocal IOLs (P = .001 and P = .008, respectively). There was greater improvement after trifocal IOL implantation in the matched cases, although not significant (P = .103).
CONCLUSIONS: Results show the Spanish version of Catquest-9SF is a valid patient questionnaire with good psychometric properties. Patients with a trifocal IOL implanted bilaterally reported better visual function than those with a monofocal IOL implanted bilaterally. The change in visual function after surgery was also greater in patients with a trifocal IOL. FINANCIAL DISCLOSURE: None of the authors has a financial or proprietary interest in any material or method mentioned.
Copyright © 2016 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28007111     DOI: 10.1016/j.jcrs.2016.10.011

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  5 in total

1.  Exploring Vision-Related Quality of Life: A Qualitative Study Comparing Patients' Experience of Cataract Surgery with a Standard Monofocal IOL and an Enhanced Monofocal IOL.

Authors:  Sergi Blancafort Alias; Zoraida Del Campo Carrasco; Ignacio Salvador-Miras; Sabina Luna Mariné; María José Gómez Prieto; Francesca Liñán Martín; Antoni Salvà Casanovas
Journal:  Clin Ophthalmol       Date:  2022-05-27

2.  Validity of the French version of Catquest-9SF and use of an electronic notepad for entering patient-reported outcome measures.

Authors:  Gregory Katz; Alexandra Rouquette; François Lignereux; Thierry Mourgues; Michel Weber; Mats Lundström
Journal:  Eye Vis (Lond)       Date:  2021-04-01

3.  Visual and satisfaction results with implantation of the trifocal Panoptix® intraocular lens in cataract surgery.

Authors:  Virgilio Galvis; Luis C Escaf; Luis J Escaf; Alejandro Tello; Lisi D Rodríguez; Ruth Lapid-Gortzak; Néstor I Carreño; Rubén D Berrospi; Camilo A Niño; Andreas Viberg; Paul A Camacho
Journal:  J Optom       Date:  2021-10-18

4.  Visual Performance, Satisfaction, and Spectacle Independence after Implantation of a New Hydrophobic Trifocal Intraocular Lens.

Authors:  Antonio Cano-Ortiz; Álvaro Sánchez-Ventosa; Timoteo González-Cruces; David Cerdán-Palacios; Vanesa Díaz-Mesa; Rubén Gallego-Ordóñez; Teresa Gálvez-Gómez; Jose A García Parrizas; Javier Zurera Baena; Alberto Villarrubia-Cuadrado
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

5.  Short term visual outcomes of a new trifocal intraocular lens.

Authors:  Jorge L García-Pérez; Juan Gros-Otero; Celia Sánchez-Ramos; Vanesa Blázquez; Inés Contreras
Journal:  BMC Ophthalmol       Date:  2017-05-17       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.